Pre-made Ieramilimab benchmark antibody ( Whole mAb, anti-CD223/LAG3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ieramilimab biosimilar, Whole Mab: Anti-CD223/LAG3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-262-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Ieramilimab biosimilar, Whole Mab: Anti-CD223/LAG3 therapeutic antibody
INN Name	Ieramilimab
Target	LAG3
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Immutep Limited;Novartis
Conditions Approved	na
Conditions Active	Breast cancer;Diffuse large B cell lymphoma;Malignant melanoma;Solid tumours
Conditions Discontinued	na
Development Tech	na